Anosmia and dysgeusia appeared early in third of our patients with mild SARS-CoV-2 infection and were short-lived in most patients.

Running title: Anosmia and dysgeusia in mild COVID-19

Keywords: SARS-CoV-2, COVID-19, Anosmia, Dysgeusia

Title: Anosmia and dysgeusia in patients with mild SARS-CoV-2 infection

Ruth Levinson, M.D.1,6*, Meital Elbaz, M.D.2,6*, Ronen Ben-Ami, M.D.2,6, David Shasha, M.D.2,6, Tal Levinson, M.D.2,6, Guy Choshen, M.D.3,6 Ksenia Petrov4,6, Avi Gadot, M.D.5,6, Yael Paran, M.D.3,6#

1. Internal medicine clinic, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
2. Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3. Internal Medicine H, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
4. Clinical Research Unit, Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
5. Department of neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

* These first authors contributed equally to this study.

#Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract (46 words)

In this cohort of 42 patients with mild COVID19 we found a unique clinical feature of acute anosmia and dysgeusia in more than third of patients. Median onset of these features was 3.3 days after onset of illness (range 0-7) with rapid recovery in most patients.
Text (1028 words)

Introduction

On March 10, 2020 an isolation unit for patients with mild coronavirus disease (COVID)-19 was opened at the Tel Aviv Medical Center (TASMC), Israel. Within the first week, we noted that many patients reported complete loss of sense of smell (anosmia) as well as altered taste sensation (dysgeusia), unrelated to appetite or nasal congestion symptoms. Anecdotally, patients described being unable to smell a lemon under their nose, or that every food they ate tasted like paper or saliva.

Here, we aimed to describe the prevalence, time of onset in relation to disease onset, and duration of anosmia and dysgeusia.

Methods

We reviewed the symptoms of hospitalized adults and adolescents (age ≥15 years) admitted to the isolation unit with COVID-19 between March 10-23, 2020. We included patients with positive PCR for SARS-CoV-2 from naso-pharyngeal swabs and mild symptoms, defined as National Early Warning Score (NEWS) 0 to 5 (1). All patients were symptomatic.

Demographic data, comorbid conditions, clinical symptoms and signs were extracted from the hospital electronic medical record system.

In addition, patients were asked to complete a questionnaire administered via mobile phone or email. A phone interview was conducted after discharge every 3-5 days until resolution of anosmia and dysgeusia, or up until 25th of March. The study was reviewed and approved by the TASMC ethics committee (approval number TLV-
0206-20). Patients were asked to give their consent to participate in the study by phone. A waiver from signed informed consent was given by the ethic committee.

The first day of illness was defined as the day of onset of the first related symptom.

**Results**

**Study population:**

Forty-five patients were admitted to the isolation unit between March 10-23, 2020, all with mild COVID-19 (NEWS score 0 to 5 at peak illness). All patients were hospitalized for observation and isolation, and none required medical therapy or supplemental oxygen. Forty-two patients (93%) completed the questionnaire and were included in our analysis. Median age was 34 years (range 15-82 years), 23 males and 19 females. 6 (9.5%) had comorbid medical conditions and 4 (4.8%) had a history of smoking (Table S1).

**Anosmia, dysgeusia and other symptoms**

Fifteen patients (35.7%) reported anosmia and 14 (33.3%) reported dysgeusia.

Fourteen patients reported both anosmia and dysgeusia, and one reported only anosmia.

Anosmia and dysgeusia started a median of 3.3 days after illness onset (range, 0 to 7 days). By the time of writing, 11 of 15 patients (73.3%) had reported recovering both their sense of smell and taste. The median duration of these symptoms was 7.1 days for dysgeusia (range, 0-7 days) and 7.6 days for anosmia (range, 4-17 days) (Figure 1). Of the remaining 4 patients, 2 reported recovering only sense of taste with ongoing
anosmia for 14 and 17 days, respectively, and 2 reported ongoing anosmia and
dysgeusia for 11 and 14 days, respectively.

Anosmia and dysgeusia were not associated with age, sex, BMI or any comorbid
condition, including smoking. However, the duration of anosmia, but not dysgeusia,
was significantly longer for patients older than 40 years of age (mean duration, 11.5
days versus 6.1 days for patients younger than 40 years; P=0.01).

Prevalence of other symptoms during the course of illness is shown in supplementary
Table 2. The most common symptoms were cough (69%), fatigue (69%), fever ≥ 38.0⁰C (66.6%) and myalgia and/or arthralgia (57%). Nine patients (21.4%) had diarrhea
and 7 (16.67%) had abdominal pain.

Anosmia and dysgeusia were more frequent in patients with sore throat (anosmia,
69.2% versus 20.7%; P=0.005 ; dysgeusia, 61.5% and 20.7%; P=0.015 ) and anosmia
was more frequent in patients with dyspnea (55.6% and 20.8%; P=0.02). Anosmia
and dysgeusia were not associated with other symptoms, including coryza.

Discussion

Anosmia and hyposmia, the inability or decreased ability to smell, is estimated to
afflict 3%–20% of the population, increasing in frequency with age (2). Patients often
have difficulty discriminating between smell and taste dysfunction (3). Moreover,
these common disorders are often overlooked by medical professionals (3, 4). Acute
onset anosmia usually follows viral infections or trauma (5). Upper respiratory tract
infection is one of the most commonly identified causes of olfactory loss, accounting
for 22% to 36% of cases(6).
We found that anosmia or dysgeusia are common in patients with mild COVID-19 and were self-reported by more than a third of patients. In contrast to post-viral anosmia and dysgeusia reported with common cold or influenza, symptoms appeared early (median of 3.3 days) after COVID-19 onset, rather than after illness resolution (7). Moreover, anosmia and dysgeusia were short lived and resolved within approximately 7 days in most patients with COVID-19, whereas recovery time is typically several weeks to months for other post-viral diseases (8, 9). Patients younger than 40 years recovered olfaction more rapidly than patients older than 40 years.

The mechanism of smell disorder in post-viral anosmia is believed to be viral damage to the olfactory epithelium independent of nasal congestion (2). The volume of the olfactory bulbs is known to be decreased in post-infectious olfactory dysfunction and correlates with olfactory function and even serve as prognostic factor in these patients (10). In a recent case report by Eliezer et al (11) a patient with COVID-19 and complete olfactory loss had a bilateral obstructive inflammation of the olfactory clefts on imaging without other nasal obstruction or rhinorrhea, and no anomalies of the olfactory bulbs and tracts. This upper obstruction presumably prevented odorant molecules from reaching the olfactory epithelium.

These findings are compatible with our results, showing no association between anosmia or dysgeusia and coryza. In fact, fewer than half the patients with these symptoms had coryza.

The incidence of postinfectious smell dysfunction associated with coronaviruses other than SARS-Cov-2 has been reported only in a limited number of studies (12). COVID-19 emerged in Wuhan, China, in November 2019 and has rapidly became pandemic. Early onset anosmia/dysgeusia are unique clinical features that might help
differentiate COVID-19 from other common respiratory viral infections, such as influenza. This is of particular importance in primary care and in resource-limited settings, where rapid molecular diagnostic testing may not be readily available.

In the reality of a pandemic which infected more the 1.5 million people worldwide and the limitation in virologic confirmation test, familiarity with a unique symptom like this could help the primary physician in triaging which patients should be referred to virologic testing by naso pharyngeal swabs.

Funding: None

Acknowledgments: None

Biographical Sketch: Dr Ruth Levinson is a specialist in internal medicine and a senior physician at the Internal Medicine Consultation Department of the Tel Aviv Sourasky Medical Center. She is currently heading the Special COVID-19 Isolation Unit at the same institution. Her interests include diagnosis of complex medical cases and, more recently, researching the clinical presentation and natural history of COVID-19.

Corresponding author: Dr. Yael Paran

Email: yaelp@tlvmc.gov.il

Infectious diseases unit, Tel Aviv Sourasky Medical Center

6th Weissman street Tel Aviv 6423906, Israel.

Tel: +972-3-6974347 Fax: +972-3-6974996
References


Table 1. Prevalence of Symptoms:

<table>
<thead>
<tr>
<th>Symptom</th>
<th>No. of Patients with the symptom</th>
<th>Prevalence (%) Total N=42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cough</td>
<td>29</td>
<td>69</td>
</tr>
<tr>
<td>Fatigue</td>
<td>29</td>
<td>69</td>
</tr>
<tr>
<td>Fever per History 37.9-37.9</td>
<td>9</td>
<td>21</td>
</tr>
<tr>
<td>Fever per History ≥38.0</td>
<td>28</td>
<td>67</td>
</tr>
<tr>
<td>Myalgia or arthralgia</td>
<td>24</td>
<td>57</td>
</tr>
<tr>
<td>Headache</td>
<td>20</td>
<td>48</td>
</tr>
<tr>
<td>Coryza</td>
<td>17</td>
<td>40</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>18</td>
<td>43</td>
</tr>
<tr>
<td>Anosmia</td>
<td>14</td>
<td>33</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>15</td>
<td>36</td>
</tr>
<tr>
<td>Sore Throat</td>
<td>13</td>
<td>31</td>
</tr>
<tr>
<td>Dizziness</td>
<td>9</td>
<td>21</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>9</td>
<td>21</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>7</td>
<td>17</td>
</tr>
<tr>
<td>Nausea or vomiting</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Palpitation</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>Chills</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Chest pain</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>hemoptysis</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>
Figure 1: Duration and timing of anosmia and dysgeusia in 14 patients.

* One patient whose symptoms lasted for 5 days is not shown since start of symptoms is unknown.

** Day 1 is the day of the first symptom during illness.
Appendix material

Supplementary Table 1: Comorbid medical conditions in patients with mild COVID-19

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Number of patients (total=42)</th>
<th>Percent of patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHD</td>
<td>5</td>
<td>11.9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5</td>
<td>11.9</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4</td>
<td>9.5</td>
</tr>
<tr>
<td>Asthma</td>
<td>3</td>
<td>7.1</td>
</tr>
<tr>
<td>OSA</td>
<td>1</td>
<td>2.4</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td>1</td>
<td>2.4</td>
</tr>
<tr>
<td>Current smoking</td>
<td>3</td>
<td>7.1</td>
</tr>
<tr>
<td>Past smoking</td>
<td>1</td>
<td>2.4</td>
</tr>
</tbody>
</table>

*None of the patients suffered from dementia, CVA/TIA, cancer. HIV, chronic renal failure or cirrhosis*